Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563829 · ClinicalTrials.gov registry record · Phase 1
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
A Phase 1 study, sponsored by NextPoint Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT07563829 is a Phase 1 study that has not yet begun recruiting, run by NextPoint Therapeutics. The registered enrollment target is 81 participants.
The verdict
NCT07563829, a Phase 1 study, has not yet begun recruiting, sponsored by NextPoint Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.
Interventions
- DRUG NPX372
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07563829
The ClinicalTrials.gov registry entry for NCT07563829 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NextPoint Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPX372 is the first listed.
NCT07563829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07563829 about?
NCT07563829 is a clinical study titled "NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies". NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer c...
What is the current status of trial NCT07563829?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2026-04-01. Estimated completion is 2027-07-01.
What interventions are being tested in trial NCT07563829?
The interventions under investigation include: NPX372 (DRUG).
Who is sponsoring clinical trial NCT07563829?
This trial is sponsored by NextPoint Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.